Geniosporum Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-12-2024
- Paid Up Capital ₹ 1.00 M
as on 26-12-2024
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2020
- Revenue 72.83%
(FY 2020)
- Profit 101.59%
(FY 2020)
- Ebitda 101.88%
(FY 2020)
- Net Worth 1.93%
(FY 2020)
- Total Assets 59.80%
(FY 2020)
About Geniosporum Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Amit Choudhary, Ankesh Ranjan, Saurav Suman, and One other member serve as directors at the Company.
- CIN/LLPIN
U74994DL2018PTC329947
- Company No.
329947
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Feb 2018
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Geniosporum Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saurav Suman  | Director | 24-Feb-2018 | Current |
| Amit Choudhary | Director | 24-Feb-2018 | Current |
| Amit Kumar | Director | 24-Feb-2018 | Current |
| Ankesh Ranjan | Director | 24-Feb-2018 | Current |
Financial Performance of Geniosporum Pharmaceuticals.
Geniosporum Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 72.83% increase. The company also saw a substantial improvement in profitability, with a 101.59% increase in profit. The company's net worth moved up by a moderate rise of 1.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Geniosporum Pharmaceuticals?
In 2020, Geniosporum Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nestiva Info Solution LlpActive 7 years 4 monthsAmit Choudhary, Ankesh Ranjan and 1 more are mutual person
- Nestiva Constructions Private LimitedActive 8 years 4 months
Amit Choudhary, Ankesh Ranjan and 1 more are mutual person
- Applicada Soft Private LimitedActive 5 years 10 months
Amit Choudhary and Ankesh Ranjan are mutual person
- Nestiva Healthcare Private LimitedActive 9 years 11 months
Amit Choudhary and Ankesh Ranjan are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Geniosporum Pharmaceuticals?
Unlock and access historical data on people associated with Geniosporum Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Geniosporum Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Geniosporum Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
